AKTS Financials

Income Statement
MetricQ2 2026Q1 2026Q1 2025Q4 2024Q3 2024
Revenue
3.4M
+4.9%
3.2M
-64.3%
9.0M
+54.2%
5.9M
-22.0%
7.5M
Cost of Revenue
0
0
-100.0%
4.7M
-27.2%
6.5M
-9.4%
7.2M
Gross Profit
3.4M
+4.9%
3.2M
-25.0%
4.3M
+777.5%
-635000
-281.9%
349.0K
Operating Expenses
32.3M
+24.5%
25.9M
+159.2%
10.0M
-80.0%
50.1M
+118.1%
23.0M
R&D
25.3M
+26.2%
20.0M
+643.7%
2.7M
-62.9%
7.3M
+21.6%
6.0M
SG&A
7.0M
+18.8%
5.9M
-15.1%
6.9M
-6.6%
7.4M
-16.8%
8.9M
Operating Income
-28899000
-27.3%
-22706000
-298.2%
-5702000
+88.8%
-50704000
-124.3%
-22608000
EBITDA
-28020000
-27.1%
-22054000
-432.6%
-4141000
-3.3%
-4008000
+79.5%
-19567000
Net Income
-24144000
-31.8%
-18325000
-185.4%
-6420000
+94.1%
-108803000
-366.8%
-23308000
EPS (Basic)
$-0.44
-15.8%
$-0.38
-850.0%
$-0.04
+95.6%
$-0.91
-250.0%
$-0.26
EPS (Diluted)
$-0.44
-15.8%
$-0.38
-850.0%
$-0.04
+95.6%
$-0.91
-250.0%
$-0.26
Shares (Diluted)
55.3M
+13.7%
48.6M
-68.5%
154.4M
+29.0%
119.7M
+31.1%
91.3M
Aktis Oncology (AKTS) โ€” Financials